Sarepta Therapeutics (SRPT) Short-term Investments (2013 - 2026)

Sarepta Therapeutics' Short-term Investments history runs 14 years deep, the most recent figure standing at $188.7 million for Q1 2026.

• On a quarterly basis, Short-term Investments fell 33.05% year-over-year to $188.7 million in Q1 2026; TTM through Mar 2026 was $188.7 million, a 33.05% decrease from a year earlier, with the FY2025 full-year figure at $138.4 million, down 45.04% from the prior year.
• Short-term Investments grew to $188.7 million in Q1 2026 per SRPT's latest filing, from $138.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $1.2 billion in Q4 2023 and bottomed at $44.6 million in Q3 2024.
• The 5-year median for Short-term Investments is $963.5 million (2024), against an average of $695.7 million.
• Across the five-year window, Short-term Investments soared 3431.67% in 2022 and slumped 96.26% in 2024, its largest moves.
• Year by year, Short-term Investments stood at $1.0 billion in 2022, then rose by 22.02% to $1.2 billion in 2023, then tumbled by 79.82% to $251.8 million in 2024, then tumbled by 45.04% to $138.4 million in 2025, then surged by 36.4% to $188.7 million in 2026.
• Per Business Quant, the three latest SRPT Short-term Investments figures stand at $188.7 million (Q1 2026), $138.4 million (Q4 2025), and $237.9 million (Q3 2025).